Krystal Biotech (KRYS) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Acidification Climate Conservation Contaminant Environment Environmental Environmental Protection Green Hazard Materials Natural Resources Nature Offset Package Packaging Pandemic Pollution Raw Materials Regenerative Toxic Waste Water Access African American Asian Benefits Black Community Culture Customer Cyber Cyber Security Data Security Death Demographic Demographics Disability Diversity Drug Pricing Employee Engagement Ethnicity Gender Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injuries Injury Latinx LGBTQ Perquisites Privacy Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skill Skilled Skills Social Societal Society Stakeholder Supplier Supply Chain Talent Training Union Volunteer Workers Workforce Assessment Assurance Audit Bonus Bribe Chronic Classified Classified Board Commitment Conflict of Interest Corporate Governance Corporate Purpose Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Materiality Mission Oversee Oversight Perquisite Plaintiff Pledging Poison Pill Procurement Purpose Quality Standard R&D Recoup Reputation Reputational Research and Development Responsibility Responsible Self-evaluation Strategy Sustainable Tax Tenure Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On May 20, 2022, Krystal Biotech, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below are the matters acted upon at the Annual Meeting and the final voting results on each matter.

Proposal One: Election of Class II Directors

The Company’s stockholders elected Daniel S. Janney, Dino A. Rossi, and E. Rand Sutherland as members of the Company’s Board of Directors as Class II directors for a three-year term. The results of the vote were as follows:

Nominee	Votes For	Votes Withheld	Broker Non-Votes

Daniel S. Janney	16,477,053	3,359,641	2,292,505
Dino A. Rossi	16,642,737	3,193,957	2,292,505
E. Rand Sutherland	19,828,360	8,334	2,292,505

Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The results of the vote were as follows:


Votes For	Votes Against	Abstentions
21,966,753	3,157	159,289

Proposal Three: Non-Binding, Advisory Vote On Named Executive Officer Compensation

The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2021, as disclosed in the Company’s proxy statement for the Annual Meeting pursuant to the compensation disclosure rules of the Securities and Exchange Commission. The results of the vote were as follows:

Votes For						Votes Against						Abstentions						Broker Non-Votes

16,441,350						3,335,424						59,920						2,292,505

Proposal Four: Non-Binding, Advisory Vote on the Frequency of Advisory Votes on Named Executive Officer Compensation

The Company’s stockholders recommended, on an advisory (non-binding) basis, every year as the frequency of future advisory votes on the compensation of the Company’s named executive officers. The results of the vote were as follows:


Every Year	Two Years	Three Years	Abstentions
19,579,383	1,326	196,689	59,296

Based on these voting results, and the recommendation of the Company’s Board of Directors that was included in the proxy statement for the Annual Meeting, the Company has determined that it will hold future advisory votes on the compensation of the Company’s named executive officers on an annual basis until the next stockholder advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers.